DK1200583T3 - Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber - Google Patents

Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber

Info

Publication number
DK1200583T3
DK1200583T3 DK00944034T DK00944034T DK1200583T3 DK 1200583 T3 DK1200583 T3 DK 1200583T3 DK 00944034 T DK00944034 T DK 00944034T DK 00944034 T DK00944034 T DK 00944034T DK 1200583 T3 DK1200583 T3 DK 1200583T3
Authority
DK
Denmark
Prior art keywords
specific binding
beta
preparation
binding properties
fold sheet
Prior art date
Application number
DK00944034T
Other languages
Danish (da)
English (en)
Inventor
Ulrike Fiedler
Rainer Rudolph
Original Assignee
Scil Proteins Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins Gmbh filed Critical Scil Proteins Gmbh
Application granted granted Critical
Publication of DK1200583T3 publication Critical patent/DK1200583T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
  • Wrappers (AREA)
  • Laminated Bodies (AREA)
DK00944034T 1999-07-13 2000-07-13 Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber DK1200583T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19932688A DE19932688B4 (de) 1999-07-13 1999-07-13 Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
PCT/EP2000/006698 WO2001004144A2 (de) 1999-07-13 2000-07-13 Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften

Publications (1)

Publication Number Publication Date
DK1200583T3 true DK1200583T3 (da) 2007-02-19

Family

ID=7914599

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00944034T DK1200583T3 (da) 1999-07-13 2000-07-13 Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber

Country Status (12)

Country Link
US (2) US7601803B1 (zh)
EP (2) EP1780279A1 (zh)
JP (2) JP4221174B2 (zh)
CN (2) CN1371415A (zh)
AT (1) ATE342359T1 (zh)
AU (1) AU5827800A (zh)
CA (1) CA2378871C (zh)
DE (2) DE19932688B4 (zh)
DK (1) DK1200583T3 (zh)
ES (1) ES2273705T3 (zh)
PT (1) PT1200583E (zh)
WO (1) WO2001004144A2 (zh)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
EA013615B1 (ru) 2004-11-12 2010-06-30 Байер Шеринг Фарма Акциенгезельшафт Рекомбинантный онколитический парамиксовирус и его применение
ATE534662T1 (de) 2005-01-03 2011-12-15 Hoffmann La Roche Methode zur identifizierung einer nukeinsäure kodierend für eine hemopexin-ähnliche struktur mit spezifischer bindung zu einem vorgegebenen molekul
US7611847B2 (en) 2005-06-01 2009-11-03 Agency For Science, Technology And Research Method for identifying an intestinal phenotype
WO2007061684A1 (en) 2005-11-18 2007-05-31 Board Of Regents, The University Of Texas System Quantification of fusion proteins and their activity from chromosomal translocation
EP1989529A4 (en) 2006-02-13 2010-09-01 Agency Science Tech & Res PROCESS FOR PROCESSING A BIOLOGICAL AND / OR CHEMICAL SAMPLE
EP2004328B1 (en) 2006-03-09 2014-06-04 Agency for Science, Technology and Research Method for performing a reaction in a droplet
WO2007139397A1 (en) 2006-05-26 2007-12-06 Waikatolink Limited Ob fold domains
EP1862803A1 (en) 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP1925664A1 (en) * 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
WO2008063135A1 (en) 2006-11-24 2008-05-29 Agency For Science, Technology And Research Apparatus for processing a sample in a liquid droplet and method of using the same
US9874501B2 (en) 2006-11-24 2018-01-23 Curiox Biosystems Pte Ltd. Use of chemically patterned substrate for liquid handling, chemical and biological reactions
JP2010523652A (ja) 2007-04-13 2010-07-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 腫瘍発生を制御する方法および腫瘍発生のリスクを診断する方法
WO2008136769A1 (en) * 2007-05-03 2008-11-13 Nanyang Technological University Online contaminant detection and removal system
SG150405A1 (en) 2007-08-29 2009-03-30 Agency Science Tech & Res Method of coating a particle
SG187477A1 (en) 2007-09-26 2013-02-28 U3 Pharma Gmbh Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
US10725020B2 (en) 2007-11-14 2020-07-28 Curiox Biosystems Pte Ltd. High throughput miniaturized assay system and methods
WO2013114217A1 (en) 2012-02-05 2013-08-08 Curiox Biosystems Pte Ltd. Array plates and methods for making and using same
US20110030874A1 (en) * 2007-11-28 2011-02-10 Agency For Science, Technology And Research Low temperature method of bonding substrates having at least one surface that includes a layer of su8
DE202008000834U1 (de) 2008-01-21 2008-05-29 Chin, Li-Te Zusammensetzung und Reagenz für CTLA-4 und Verwendungen derselben
EP2085092A1 (en) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
EP2090890A1 (en) 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
JP2011522520A (ja) 2008-05-06 2011-08-04 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 細胞の脱分化を行う方法
US20110144198A1 (en) 2008-05-16 2011-06-16 Atlas Antibodies Ab Breast cancer prognostics
WO2010086400A1 (en) 2009-01-30 2010-08-05 Atlas Antibodies Ab Combination treatment of breast cancer
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
US9115340B2 (en) 2008-08-08 2015-08-25 Agency For Science Technology & Research Microfluidic continuous flow device
EP2161577A1 (en) 2008-09-01 2010-03-10 Atlas Antibodies AB ANLN protein
EP2172477A1 (en) 2008-10-06 2010-04-07 Atlas Antibodies AB Epitopes derived from SATB2 and uses thereof
US8716420B2 (en) 2008-10-13 2014-05-06 Agency For Science, Technology And Research Amphiphilic polymers and nanocrystals coated therewith
EP2379718B2 (en) 2008-12-16 2020-12-30 Novartis AG Yeast display systems
EP2241889A1 (en) 2009-04-16 2010-10-20 Atlas Antibodies AB RBM3 protein in colorectal cancer prognostics
AU2009339802B2 (en) 2009-02-16 2014-07-24 Atlas Antibodies Ab RBM3 as a marker for malignant melanoma prognosis
EP2293070A1 (en) 2009-08-13 2011-03-09 Atlas Antibodies AB Means and methods for ovarian cancer prognosis
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
US8784752B2 (en) 2009-04-17 2014-07-22 Curiox Biosystems Pte Ltd Use of chemically patterned substrate for liquid handling, chemical and biological reactions
BRPI1016055A2 (pt) 2009-04-27 2016-05-10 Novartis Ag composição e métodos de uso para anticorpos terapêuticos específicos para a subunidade beta i do receptor de il-12
CA2758290C (en) 2009-04-27 2018-04-10 Novartis Ag Antagonistic activin receptor iib (actriib) antibodies for increasing muscle growth
EP2259059A1 (en) 2009-05-29 2010-12-08 Atlas Antibodies AB Means and methods for ovarian cancer prognosis
SG177395A1 (en) 2009-07-07 2012-02-28 Agency Science Tech & Res Methods of identifying a pair of binding partners
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
WO2011054644A1 (en) 2009-10-14 2011-05-12 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. A low density lipoprotein-related protein 1 splice variant as cancer marker
EP2315028A1 (en) 2009-10-26 2011-04-27 Atlas Antibodies AB PODXL protein in colorectal cancer
WO2011080050A2 (en) 2009-12-11 2011-07-07 Novartis Ag Binding molecules
BR112012014194A2 (pt) * 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos
EP2552938B1 (en) 2010-03-31 2016-03-02 Agency for Science, Technology And Research Amphiphilic linear peptide/peptoid and hydrogel comprising the same
JP2013527761A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
EP2390665A1 (en) 2010-05-27 2011-11-30 Atlas Antibodies AB Prostate cancer biomarkers
US9878328B2 (en) 2010-07-23 2018-01-30 Curiox Biosystems Pte Ltd. Apparatus and method for multiple reactions in small volumes
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN103154037A (zh) 2010-10-05 2013-06-12 诺瓦提斯公司 抗IL12Rβ1抗体及它们在治疗自身免疫病和炎性疾病中的用途
CA2815267C (en) 2010-10-27 2019-06-25 Spiber Technologies Ab Spider silk fusion protein structures for binding to an organic target
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
WO2012172055A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
HUE040276T2 (hu) 2011-07-01 2019-02-28 Novartis Ag Eljárás metabolikus rendellenességek kezelésére
EP2544007A1 (en) 2011-07-07 2013-01-09 Atlas Antibodies AB Biomarker of renal impairment
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
EP2573566A1 (en) 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
EP2769223A1 (en) 2011-10-17 2014-08-27 Westfälische Wilhelms-Universität Münster Assessment of pml risk and methods based thereon
JP6243345B2 (ja) 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
EP2602622A1 (en) 2011-12-07 2013-06-12 Atlas Antibodies AB Prediction of response to platinum-based therapy
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
AU2012324020A1 (en) 2011-12-30 2013-07-18 Grifols, S.A. Method for purifying Factor VIII
CA2865033C (en) 2012-02-23 2021-11-02 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
ES2529018T3 (es) 2012-04-02 2015-02-16 F. Hoffmann-La Roche Ag Métodos y uso para la evaluación de la gravedad de la enfermedad pulmonar obstructiva crónica (EPOC)
EP2844360B1 (en) 2012-05-02 2018-12-19 Spiber Technologies AB Spider silk fusion protein structures without repetitive fragment for binding to an organic target
WO2013189521A1 (en) 2012-06-19 2013-12-27 Waclawczyk Simon Method of generating cells of hepatocyte phenotype
EP2687850A1 (en) 2012-07-19 2014-01-22 Roche Diagniostics GmbH Methods of stratifying for respiratory support therapy
SG11201501382YA (en) 2012-08-27 2015-03-30 Univ Nanyang Tech Nanoparticulate contrast agent
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US20150210768A1 (en) 2012-09-10 2015-07-30 Westfaelische Wilhelms-Universitaet Muenster Methods and Compounds for Preventing, Treating and Diagnosing an Inflammatory Condition
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
JP6306605B2 (ja) 2012-12-05 2018-04-04 ノバルティス アーゲー Ｅｐｏを標的とする抗体のための組成物および方法
EP2746768A1 (en) 2012-12-20 2014-06-25 Atlas Antibodies AB Podxl in bladder cancer
EA031537B1 (ru) 2013-02-08 2019-01-31 Новартис Аг Антитела против il-17a и их применение для лечения аутоиммунных и воспалительных нарушений
WO2014141064A1 (en) 2013-03-13 2014-09-18 Novartis Ag Notch2 binding molecules for treating respiratory diseases
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
WO2014140197A1 (en) 2013-03-15 2014-09-18 Westfaelische Wilhelms-Universitaet Muenster Detection of acute renal allograft rejection
EP2787350A1 (en) 2013-04-05 2014-10-08 Atlas Antibodies AB ASRGL1 in endometrial cancer
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
US9557318B2 (en) 2013-07-09 2017-01-31 Curiox Biosystems Pte Ltd. Array plates for washing samples
NZ746944A (en) 2013-07-23 2021-07-30 Biocon Ltd Use of a cd6 binding partner and method based thereon
AU2014307589A1 (en) 2013-08-14 2016-02-11 Novartis Ag Methods of treating sporadic inclusion body myositis
US10203327B2 (en) 2013-11-05 2019-02-12 Novartis Ag Organic compounds
EP3071217A2 (en) 2013-11-18 2016-09-28 Westfälische Wilhelms-Universität Münster Methods, peptides and antibodies for preventing, treating and diagnosing an inflammatory condition
LU92409B1 (en) 2014-03-21 2015-09-22 Philipps Universit T Marburg Means and methods for itaconic acid production
WO2015158868A2 (en) 2014-04-16 2015-10-22 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
AU2015254588B2 (en) 2014-04-30 2020-05-21 Iba Gmbh Method of isolating a target cell
CN104059119A (zh) * 2014-06-10 2014-09-24 高海岗 雌二醇半抗原、抗原、抗体及其制备方法与应用
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
KR20240056627A (ko) 2014-08-07 2024-04-30 노파르티스 아게 안지오포이에틴-유사 4 항체 및 사용 방법
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3023791A1 (en) 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
EP3253785B1 (en) 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
WO2016166568A1 (en) 2015-04-16 2016-10-20 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
WO2016193872A2 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
US10545139B2 (en) 2015-06-16 2020-01-28 Curiox Biosystems Pte Ltd. Methods and devices for performing biological assays using magnetic components
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
KR102064396B1 (ko) 2015-07-16 2020-01-09 나피고 프로타인스 게엠베하 신규한 면역글로불린-결합 단백질 및 친화도 정제에서의 이의 용도
JP2018520675A (ja) 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
NZ740067A (en) 2015-09-09 2021-07-30 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
AU2016341527B2 (en) 2015-10-22 2023-04-27 Juno Therapeutics Gmbh Methods, kits, agents and apparatuses for transduction
US20170198040A1 (en) 2015-12-18 2017-07-13 Novartis Ag ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
US11230576B2 (en) 2016-08-11 2022-01-25 Navigo Proteins Gmbh Alkaline stable immunoglobulin-binding proteins
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
KR20240014600A (ko) 2017-03-24 2024-02-01 노바르티스 아게 심장질환 예방 및 치료 방법
KR20220132668A (ko) 2017-04-05 2022-09-30 큐리옥스 바이오시스템즈 피티이 엘티디. 어레이 플레이트 상의 샘플을 세정하기 위한 방법, 디바이스 및 장치
JP7339160B2 (ja) 2017-04-27 2023-09-05 ジュノ セラピューティクス ゲーエムベーハー オリゴマー粒子試薬およびその使用方法
EP3618861A1 (en) 2017-05-02 2020-03-11 Bayer Aktiengesellschaft Tmem16a modulation for diagnostic or therapeutic use in pulmonary hypertension (ph)
CN107163261B (zh) * 2017-05-04 2019-12-06 苏州大学 一种丝素蛋白乳状液滴及其制备方法
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
JP2020525421A (ja) 2017-06-28 2020-08-27 ノバルティス アーゲー 尿失禁を予防及び治療するための方法
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
AU2018358804A1 (en) 2017-11-02 2020-04-09 Bayer Aktiengesellschaft Bispecific antibodies binding ALK-1 and BMPR-2
US11414466B2 (en) 2017-11-07 2022-08-16 Navigo Proteins Gmbh Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
CA3083210A1 (en) 2017-11-22 2018-11-20 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020043693A1 (en) 2018-08-29 2020-03-05 Westfälische Wilhelms-Universität Münster Diagnosis of multiple sclerosis
DE102018124022A1 (de) 2018-09-28 2020-04-02 Rheinisch-Westfälische Technische Hochschule (Rwth) Aachen Hyaluronsäurestabilisator
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
US20220025070A1 (en) 2018-12-18 2022-01-27 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
TWI809286B (zh) 2019-07-05 2023-07-21 日商小野藥品工業股份有限公司 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療
JPWO2021025140A1 (zh) 2019-08-08 2021-02-11
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
US11802141B2 (en) 2019-10-25 2023-10-31 University Of Washington De novo designed non-local beta sheet proteins
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
EP4004545B1 (en) 2020-01-31 2022-11-02 Cell.copedia GmbH Methods of isolating a biological entity
CA3208778A1 (en) 2021-01-22 2022-07-28 Bayer Aktiengesellschaft Lrrc15 antibodies and conjugates thereof
US20240183855A1 (en) 2021-03-30 2024-06-06 Westfaelische Wilhelms-Universitaet Muenster Classification of neurological or psychiatric disease manifestations using multi-dimensional cerebrospinal fluid analysis
KR20240004462A (ko) 2021-04-08 2024-01-11 마렝고 테라퓨틱스, 인크. Tcr에 결합하는 다기능성 분자 및 이의 용도
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
WO2023017115A1 (en) 2021-08-11 2023-02-16 Iba Lifesciences Gmbh Fractionation of cells based on a marker protein
WO2023217904A1 (en) 2022-05-10 2023-11-16 Institut National de la Santé et de la Recherche Médicale Syncitin-1 fusion proteins and uses thereof for cargo delivery into target cells
EP4379375A1 (en) 2022-12-01 2024-06-05 Universität Münster Classification of connective tissue disease with neurological manifestation using multi-dimensional peripheral blood analysis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) * 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
WO1997012992A2 (en) * 1995-10-02 1997-04-10 Royal Netherlands Academy Of Arts And Sciences Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore
CA2235223A1 (en) * 1995-10-30 1997-05-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from heparinase i
US5789166A (en) * 1995-12-08 1998-08-04 Stratagene Circular site-directed mutagenesis
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
FR2761688A1 (fr) * 1997-04-02 1998-10-09 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
FR2761689B1 (fr) 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
DE69818458T3 (de) * 1997-05-28 2009-12-17 Crescendo Biologics Ltd., Babraham Ribosom-komplexe als selektionspartikel für die in vitro anzeige und evolution von proteinen
ES2301198T3 (es) * 1997-06-12 2008-06-16 Novartis International Pharmaceutical Ltd. Polipeptidos artificiales de anticuerpos.
DE19742706B4 (de) * 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
TWI259837B (en) 1998-05-11 2006-08-11 Eidgenossische Tech Hochscule Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
CA2399866C (en) 2000-02-24 2011-05-10 Philogen S.R.L. Compositions and methods for treatment of angiogenesis in pathological lesions
CA2400622A1 (en) 2000-02-24 2001-08-30 Eidgenossische Technische Hochschule Zurich Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
US6799121B2 (en) * 2000-03-30 2004-09-28 York University Sequencing of peptides by mass spectrometry
US20040043386A1 (en) * 2002-08-30 2004-03-04 Todd Pray Methods and compositions for functional ubiquitin assays
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
CA2544764A1 (en) 2003-11-04 2005-05-19 Yale University Protein binding miniature proteins
WO2005059131A2 (en) 2003-12-11 2005-06-30 Yale University Protein binding miniature proteins and uses thereof
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
ATE459648T1 (de) 2005-05-11 2010-03-15 Philogen Spa Fusionsprotein von antikörper l19 gegen fibronectin ed-b und interleukin 12
JP2009514540A (ja) 2005-11-09 2009-04-09 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 機能−阻止抗−ｅｄ−ｂ−フィブロネクチン抗体（ｐｒｉｖａｔｅ）の同定及び特徴化
EP1842553A1 (en) 2006-04-07 2007-10-10 Bayer Schering Pharma Aktiengesellschaft Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule
WO2007128563A1 (en) 2006-05-08 2007-11-15 Philogen Spa Antibody-targeted cytokines for therapy
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
EP1925664A1 (en) 2006-11-15 2008-05-28 Scil proteins GmbH Artificial binding proteins based on a modified alpha helical region of ubiquitin
EP1955712A1 (en) 2007-02-09 2008-08-13 Scil proteins GmbH Multimeric conjugate
BR112012014194A2 (pt) 2009-12-14 2017-01-10 Scil Proteins Gmbh um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos

Also Published As

Publication number Publication date
PT1200583E (pt) 2006-12-29
WO2001004144A2 (de) 2001-01-18
CN1371415A (zh) 2002-09-25
WO2001004144A3 (de) 2001-08-02
JP2008019276A (ja) 2008-01-31
JP4597177B2 (ja) 2010-12-15
US20070111287A1 (en) 2007-05-17
EP1200583A2 (de) 2002-05-02
ATE342359T1 (de) 2006-11-15
EP1780279A1 (de) 2007-05-02
CA2378871C (en) 2012-04-17
ES2273705T3 (es) 2007-05-16
DE50013610D1 (de) 2006-11-23
EP1200583B1 (de) 2006-10-11
CN101693889A (zh) 2010-04-14
JP2003504081A (ja) 2003-02-04
DE19932688A1 (de) 2001-01-18
AU5827800A (en) 2001-01-30
CA2378871A1 (en) 2001-01-18
US8592144B2 (en) 2013-11-26
US7601803B1 (en) 2009-10-13
DE19932688B4 (de) 2009-10-08
JP4221174B2 (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
DK1200583T3 (da) Fremstilling af beta-foldeblad-proteiner med specifikke bindingsegenskaber
DE502004012225D1 (de) Generierung künstlicher bindungsproteine auf der grundlage von ubiquitin-proteinen
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
CY1119263T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
EP2330129A3 (en) Anti-TNF antibodies, compositions, methods and uses
CY1106806T1 (el) Dna και πολυπεπτιδια ανθρωπινης tslp
EP1832599A3 (en) Albumin fusion proteins
EP2330197A3 (en) Antagonistic selective binding agents of osteoprotegerin binding protein
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
WO2001012659A3 (en) Human dna sequences
AU3075995A (en) Process for modifying the stability of antibodies
GB9722320D0 (en) Human cell cycle checkpoint proteins
DK0781341T3 (da) Fremgangsmåde til fremstilling af rekombinante proteiner, plasmider og modificerede celler
AU1239997A (en) Polypeptides corresponding to the amino acid sequences of proteins p57 or p9.5 of Borna disease virus, nucleic acid fragments coding therefore and their use for diagnostic and immunization purposes
SE9602822D0 (sv) New receptor
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
AUPM772494A0 (en) Improvements in production of proteins in host cells
WO2002062964A3 (en) Ap1 amine oxidase variants
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
WO2003104449A3 (en) IMPROVEMENTS IN PROTEIN PRODUCTION
ATE291589T1 (de) Immunologische bindungsmoleküle, die die synzytiale fusion von trophoblastzellen hemmen
WO2004069989A3 (en) Novel purified phosphodiesterase polypeptides
WO2005003289A8 (en) Ap1 amine oxidase variants